Cumberland Pharmaceuticals has secured an expanded FDA indication for its Caldolor (ibuprofen) Injection, broadening the product’s approved use in the management of post‑operative pain.
The Nashville‑based specialty pharmaceutical company said the updated label now covers treatment of post‑surgical pain in adults and pediatric patients as young as three months old. Previously, Caldolor’s label focused on pain and fever management in more limited settings, and Cumberland has long positioned the intravenous formulation as a non‑opioid option for hospitalized patients.
According to the company, the expanded indication is supported by clinical data evaluating Caldolor in peri‑ and post‑operative use, including studies designed to assess both safety and analgesic efficacy. The trials examined the product’s performance in reducing pain intensity and the need for additional rescue analgesics, as well as its overall tolerability when administered intravenously in surgical populations.
Cumberland noted that Caldolor’s profile may allow clinicians to incorporate the product into multimodal pain‑management regimens aimed at reducing reliance on opioid medications following surgery. The company also highlighted ongoing Phase II development programs for its ifetroban candidate in multiple indications, but the latest regulatory action centers on strengthening the commercial position of its established hospital portfolio.
Caldolor is an injectable formulation of ibuprofen, a nonsteroidal anti‑inflammatory drug (NSAID) that exerts its effect by inhibiting cyclooxygenase enzymes involved in prostaglandin synthesis. The product is already marketed for use in U.S. hospital and acute‑care settings, where intravenous delivery can be useful for patients who are unable to take oral medications in the immediate post‑operative period.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!